explore -WSS

explore

author：comprehensive 2025-09-30 12:18:34 - browse：28964

An army of wooden figures under blue and pink lighting — biotech coverage from STAT — Adobe

Biotech startup ReNAgade Therapeutics is cutting staff just seven months after raising the largest Series A round in the industry this year.

ReNAgade launched in May with hopes of becoming a one-stop shop for medicines targeting RNA, the genetic blueprints that cells use to make proteins instrumental in numerous diseases. These types of medicines are in high demand following the advent of mRNA vaccines for Covid and RNA-silencing therapies made by companies like Alnylam Pharmaceuticals.

ReNAgade was able to capitalize on that excitement when it raised a $300 million Series A round led by MPM Capital’s BioImpact Capital and F2 Ventures. But in recent days, the company decided to lay off around 10% of its 100-person team, according to a company statement and former employees’ posts on social media.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Bright Health sells Medicare Advantage business to Molina
Next article： Type 2 diabetes prevention programs work at large scale: study

leisure time

WSS

Study suggests Covid rebound is far more common with Paxlovid than without

CDC director unscathed in first congressional testimony

FDA investigates CAR

Disappointing trial forces Pfizer to pivot on obesity medicine plans

Readout Newsletter: Ozempic panic wanes, Legend x Novartis, etc.

Healthy food access boosts outcomes in two studies

leisure time

explore

focus

Anesthesiologist group: stop taking Ozempic before surgery

With clinical trial data readouts, here's how to spot spin

Apple is now the first public company to be valued at $3 trillion

What to do when lifesaving products contribute to climate change

Novavax promises a turnaround & Lilly roils the obesity market

FDA reorg will put new emphasis on investigations, sources say

Trump demands the U.S. pay no more for drugs than other countries … again

Cigna, Humana reportedly in talks to merge

BioMarin wins approval for gene therapy to treat hemophilia A

Despite FDA concern, risk that CAR

focus

FDA reorg will put new emphasis on investigations, sources say

Readout Newsletter: Zepbound, Valneva's vaccine, and more

Medicare’s new pay boost for primary care is angering specialists

As biotech industry slumps, bioscience job market is upside down

Diagnostic tests are hitting their mathematical limits

NIH chief: government has fallen behind pharma on clinical trials

leisure time

leisure time

entertainment

hotspot